There were 22 pharmaceutical acquisitions in the second quarter of 2020, slightly below the average of 27.
The biggest deal so far has been Gilead’s acquisition of Forty Seven for $4.9 billion, significantly lower than the average largest deal, according to EvaluatePharma.
The five largest pharmaceuticals M&A deals this year:
- Gilead’s acquisition of Forty Seven — $4.9 billion
- Novo Nordisk’s acquisition of Corvidia — $2.1 billion
- Alexion’s acquisition of Portola — $1.4 billion
- Eli Lilly’s acquisition of Dermira — $1.1 billion
- Takeda’s divestiture of select drugs to Hypera Pharma — $825 million
More articles on pharmacy:
US sues Teva for alleged MS drug kickback scheme
J&J to acquire Momenta Pharma for $6.5B
White House adviser says Kodak execs made ‘dumbest decisions’ on government loan
